Kris Persaud currently serves as a Senior Advisor for Novasenta since January 2022. He brings more than 25 years of biopharmaceutical experience in oncology biologics drug discovery and development. He has demonstrated leadership experience in antibody technology across screening, production, biophysical characterization, engineering, and cell line generation. More recently, he served as Director of Cell Expression and Engineering of oncology discovery research at Eli Lilly and Company. As a member of the Senior Leadership Team, he directly supported the development and successful launch of several biologic oncology drugs including Erbitux®, Cyramza™, Portrazza® and Lartruvo™ as well as clinical advancement of many more therapeutic antibodies over the course of his career. Prior to Lilly’s acquisition, Kris was a Senior Scientist and Team Leader at ImClone Systems Inc. providing discovery research leadership within the Angiogenesis and Tumor Biology department, developing therapeutic antibodies to receptor tyrosine kinase. Kris received his BS in Biology from The City College on New York. He has also been an author on >30 manuscripts, and abstracts including patents.